• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Talaris Therapeutics Inc.

    2/9/24 4:22:56 PM ET
    $TALS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TALS alert in real time by email
    SC 13G 1 d710578dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    Tourmaline Bio, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    89157D105

    (CUSIP Number)

    January 29, 2024

    (Date of Event Which Requires Filing of This Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 89157D105    13G

     

    1.   

    NAMES OF REPORTING PERSONS

     

    TCG Crossover GP I, LLC

    2.   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a)  ☐  (b) ☒

     

    3.   

    SEC USE ONLY

     

    4.   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

    SOLE VOTING POWER

     

    0

       6.   

    SHARED VOTING POWER

     

    1,477,593 (1)

       7.   

    SOLE DISPOSITIVE POWER

     

    0

       8.   

    SHARED DISPOSITIVE POWER

     

    1,477,593 (1)

    9.   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,477,593 (1)

    10.   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ☐

    11.   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.9% (2)

    12.   

    TYPE OF REPORTING PERSON (see instructions)

     

    OO

     

    (1)

    Consists of 1,477,593 shares of Common Stock (as defined in Item 2(d) below) of the Issuer (as defined in Item 1(a) below) held of record by TCG Crossover I (as defined in Item 2(a) below). TCG Crossover GP I (as defined in Item 2(a) below) is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP I and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 24,952,955 shares of Common Stock outstanding, as disclosed by the Issuer in its final prospectus dated January 25, 2024 and filed with the Securities and Exchange Commission (the “Commission”) on January 26, 2024 pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the “Prospectus”).


    CUSIP No. 89157D105    13G

     

    1.   

    NAMES OF REPORTING PERSONS

     

    TCG Crossover Fund I, L.P.

    2.   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a)  ☐  (b) ☒

     

    3.   

    SEC USE ONLY

     

    4.   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

    SOLE VOTING POWER

     

    0

       6.   

    SHARED VOTING POWER

     

    1,477,593 (1)

       7.   

    SOLE DISPOSITIVE POWER

     

    0

       8.   

    SHARED DISPOSITIVE POWER

     

    1,477,593 (1)

    9.   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,477,593 (1)

    10.   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ☐

    11.   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.9% (2)

    12.   

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

     

    (1)

    Consists of 1,477,593 shares of Common Stock of the Issuer held of record by TCG Crossover I. TCG Crossover GP I is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP I and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 24,952,955 shares of Common Stock outstanding, as disclosed by the Issuer in its Prospectus.


    CUSIP No. 89157D105    13G

     

    1.   

    NAMES OF REPORTING PERSONS

     

    Chen Yu

    2.   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a)  ☐  (b) ☒

     

    3.   

    SEC USE ONLY

     

    4.   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

    SOLE VOTING POWER

     

    0

       6.   

    SHARED VOTING POWER

     

    1,477,593 (1)

       7.   

    SOLE DISPOSITIVE POWER

     

    0

       8.   

    SHARED DISPOSITIVE POWER

     

    1,477,593 (1)

    9.   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,477,593 (1)

    10.   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ☐

    11.   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.9% (2)

    12.   

    TYPE OF REPORTING PERSON (see instructions)

     

    IN

     

    (1)

    Consists of 1,477,593 shares of Common Stock of the Issuer held of record by TCG Crossover I. TCG Crossover GP I is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP I and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 24,952,955 shares of Common Stock outstanding, as disclosed by the Issuer in its Prospectus.


    CUSIP No. 89157D105    13G

     

    Item 1(a).

    Name of Issuer:

    Tourmaline Bio, Inc. (the “Issuer”).

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    27 West 24th Street, Suite 702

    New York, NY 10010

     

    Item 2(a).

    Name of Person Filing:

    This joint statement on Schedule 13G is being filed by TCG Crossover Fund I, L.P. (“TCG Crossover I”), TCG Crossover GP I, LLC (“TCG Crossover GP I” and together with TCG Crossover I, the “Reporting Entities”) and Chen Yu (the “Reporting Individual”). The Reporting Entities and the Reporting Individual are collectively referred to as the “Reporting Persons.” The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G. The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached to this Statement as Exhibit 1. Other than those securities reported herein as being held directly by such Reporting Person, each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Person’s pecuniary interest therein.

     

    Item 2(b)

    Address of Principal Business Office, or if None, Residence:

    The address of the principal business office of each Reporting Person is 705 High St., Palo Alto, CA 94301.

     

    Item 2(c).

    Citizenship:

    TCG Crossover GP I is a limited liability company organized under the laws of the State of Delaware. TCG Crossover I is a limited partnership organized under the laws of the State of Delaware. The Reporting Individual is a citizen of the United States of America.

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, $0.0001 par value (“Common Stock”).

     

    Item 2(e).

    CUSIP Number:

    89157D105

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.


    CUSIP No. 89157D105    13G

     

    Item 4.

    Ownership.

    (a) Amount beneficially owned:

    See Row 9 of the cover page for each Reporting Person and the corresponding footnotes.*

    (b) Percent of class:

    See Row 11 of the cover page for each Reporting Person and the corresponding footnotes.*

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    See Row 5 of the cover page for each Reporting Person and the corresponding footnotes.*

    (ii) Shared power to vote or to direct the vote

    See Row 6 of the cover page for each Reporting Person and the corresponding footnotes.*

    (iii) Sole power to dispose or to direct the disposition of

    See Row 7 of the cover page for each Reporting Person and the corresponding footnotes.*

    (iv) Shared power to dispose or to direct the disposition of

    See Row 8 of the cover page for each Reporting Person and the corresponding footnotes.*

     

    *

    Except to the extent of his or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person.

    Under certain circumstances set forth in the limited partnership agreements of TCG Crossover I and the limited liability company agreement of TCG Crossover GP I, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of securities of the Issuer owned by each such entity of which they are a partner or member, as the case may be.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.


    CUSIP No. 89157D105    13G

     

    Item 9.

    Notice of Dissolution of the Group.

    Not applicable.

     

    Item 10.

    Certifications.

    Not Applicable

    Material to be Filed as Exhibits.

    Exhibit 1 – Joint Filing Agreement.


    CUSIP No. 89157D105    13G

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 9, 2024

     

    TCG Crossover Fund I, L.P.
    By:   TCG Crossover GP I, LLC
    Its:   General Partner
    By:   /s/ Chen Yu
      Managing Member
    TCG Crossover GP I, LLC
    By:   /s/ Chen Yu
      Managing Member
    /s/ Chen Yu
    Chen Yu

     

    Get the next $TALS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TALS

    DatePrice TargetRatingAnalyst
    10/20/2022$18.00Buy
    H.C. Wainwright
    7/5/2022$20.00 → $8.00Overweight → Equal-Weight
    Morgan Stanley
    11/12/2021$21.00 → $22.00Outperform
    SVB Leerink
    More analyst ratings

    $TALS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio

      Combined Company to Trade on Nasdaq Under Ticker "TRML"Talaris Announces 1-for-10 Reverse Stock Split of Common Stock BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris") today announced the results of the special meeting of its stockholders held on October 17, 2023. At the special meeting, Talaris' stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Talaris' common stock to the stockholders of Tourmaline Bio, Inc. ("Tourmaline") pursuant to the terms of the Agreement and Plan of Merger, dated as of June 22, 2023, pursuant to which a direct wholly owned subsidiary of Talaris will merge with a

      10/17/23 5:47:44 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio

      Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Tourmaline Bio, Inc. ("Tourmaline") pursuant to the Agreement and Plan of Merger, dated June 22, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.5118 per share of Talaris common stock, will be payable in cash. The exact amount of the sp

      10/6/23 5:09:00 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics

      NEW YORK and BOSTON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises (NYBCe) and Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris") announced today NYBCe's acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain technologies and equipment from Talaris in Houston, Texas and Louisville, Kentucky. The acquisition of both locations, combined with NYBCe's Comprehensive Cell Solutions (CCS) vast cell sourcing and collection network, accelerates the delivery of a fully integrated vein-to-vein cell and gene therapy development and manufacturing solution for the continental United States (US), capable of serving the bi

      10/4/23 8:30:00 AM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TALS
    Financials

    Live finance-specific insights

    See more
    • Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio

      Combined Company to Trade on Nasdaq Under Ticker "TRML"Talaris Announces 1-for-10 Reverse Stock Split of Common Stock BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris") today announced the results of the special meeting of its stockholders held on October 17, 2023. At the special meeting, Talaris' stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Talaris' common stock to the stockholders of Tourmaline Bio, Inc. ("Tourmaline") pursuant to the terms of the Agreement and Plan of Merger, dated as of June 22, 2023, pursuant to which a direct wholly owned subsidiary of Talaris will merge with a

      10/17/23 5:47:44 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio

      Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Tourmaline Bio, Inc. ("Tourmaline") pursuant to the Agreement and Plan of Merger, dated June 22, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.5118 per share of Talaris common stock, will be payable in cash. The exact amount of the sp

      10/6/23 5:09:00 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics

      NEW YORK and BOSTON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises (NYBCe) and Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris") announced today NYBCe's acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain technologies and equipment from Talaris in Houston, Texas and Louisville, Kentucky. The acquisition of both locations, combined with NYBCe's Comprehensive Cell Solutions (CCS) vast cell sourcing and collection network, accelerates the delivery of a fully integrated vein-to-vein cell and gene therapy development and manufacturing solution for the continental United States (US), capable of serving the bi

      10/4/23 8:30:00 AM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TALS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mcdade Mark bought $3,250,000 worth of shares (100,000 units at $32.50) (SEC Form 4)

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      1/31/24 4:26:17 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kulkarni Sandeep Chidambar bought $67,960 worth of shares (4,000 units at $16.99), increasing direct ownership by 0.55% to 729,735 units (SEC Form 4)

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      11/20/23 6:15:47 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Thiara Parvinder bought $17,310 worth of shares (1,000 units at $17.31), increasing direct ownership by 1% to 83,782 units (SEC Form 4)

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      11/20/23 6:14:25 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TALS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Talaris Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Talaris Therapeutics with a rating of Buy and set a new price target of $18.00

      10/20/22 7:24:56 AM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Talaris Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Talaris Therapeutics from Overweight to Equal-Weight and set a new price target of $8.00 from $20.00 previously

      7/5/22 7:28:16 AM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Talaris Therapeutics with a new price target

      SVB Leerink reiterated coverage of Talaris Therapeutics with a rating of Outperform and set a new price target of $22.00 from $21.00 previously

      11/12/21 9:44:40 AM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TALS
    SEC Filings

    See more
    • Talaris Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - Tourmaline Bio, Inc. (0001827506) (Filer)

      1/26/24 4:12:52 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Talaris Therapeutics Inc.

      424B5 - Tourmaline Bio, Inc. (0001827506) (Filer)

      1/26/24 4:08:02 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Talaris Therapeutics Inc.

      424B5 - Tourmaline Bio, Inc. (0001827506) (Filer)

      1/24/24 9:20:06 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TALS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mcdade Mark bought $3,250,000 worth of shares (100,000 units at $32.50) (SEC Form 4)

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      1/31/24 4:26:17 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Siegall Clay B

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      12/15/23 4:23:26 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Siegall Clay B

      3 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      12/15/23 4:21:42 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TALS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Talaris Therapeutics Inc. (Amendment)

      SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)

      2/14/24 9:08:07 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Talaris Therapeutics Inc.

      SC 13G - Tourmaline Bio, Inc. (0001827506) (Subject)

      2/14/24 8:51:41 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Talaris Therapeutics Inc. (Amendment)

      SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)

      2/14/24 5:04:58 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TALS
    Leadership Updates

    Live Leadership Updates

    See more
    • Talaris Therapeutics Announces Leadership Transition

      BOSTON and LOUISVILLE, Ky., May 26, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), today announced the appointment of Mary Kay Fenton as interim Chief Executive Officer and President effective as of today. Ms. Fenton, who will continue as Talaris's Chief Financial Officer, succeeds Chief Executive Officer Scott Requadt who will be leaving the Company as part of a planned workforce reduction, as previously announced by the Company. "On behalf of the board, I would like to thank Scott for his unwavering commitment to patients and to Talaris over the past four and a half years," said Francois Nader, MD, Chairman of the Talaris Therapeutics Board of Directors. "I welcome M

      5/26/23 7:00:00 AM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Talaris Therapeutics Announces Second Quarter Financial Results and Corporate Update

      All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date of June 15, 2022 had achieved and maintained >50% T-cell chimerism, and all three patients who were dosed at least 12 months post-transplant have discontinued their chronic anti-rejection drugs Multiple oral and poster presentations at the American Transplant Congress (ATC) 2022 highlighted key research findings and long-term Phase 2 follow up Strong cash balance with expected runway through 2024 BOSTON and LOUISVILLE, Ky., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform

      8/15/22 7:00:00 AM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Talaris Therapeutics Announces Changes to Board of Directors

      BOSTON and LOUISVILLE, Ky., May 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced the appointment of independent director Karen Smith, M.D., Ph.D., MBA, LLM to the Company's Board of Directors. "Karen's long track record of developing and commercializing novel therapies and her wide-ranging industry experience make her a valuable addition to our Board of Directors," said Francois Nader, M.D., Chairman of the Board of Talaris. "I am pleased to welcome her to the team an

      5/17/22 7:00:00 AM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care